A validated LC–MS/MS assay for the simultaneous determination of periplocin and its two metabolites, periplocymarin and periplogenin in rat plasma: Application to a pharmacokinetic study
- 1 October 2015
- journal article
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 114, 292-295
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- A validated LC–MS/MS method for determination of periplogenin in rat plasma and its application in pharmacokinetic studyJournal of Chromatography B, 2015
- Comparative Proteomic Analysis of Anti-Cancer Mechanism by Periplocin Treatment in Lung Cancer CellsCellular Physiology and Biochemistry, 2014
- Periplocymarin is a potential natural compound for drug development: highly permeable with absence of P‐glycoprotein efflux and cytochrome P450 inhibitionsBiopharmaceutics & Drug Disposition, 2013
- Antitumor Effect of Periplocin in TRAIL-Resistant Human Hepatocellular Carcinoma Cells through Downregulation of IAPsEvidence-Based Complementary and Alternative Medicine, 2013
- Periplogenin, Isolated fromLagenaria siceraria, Ameliorates L-T4-induced Hyperthyroidism and Associated Cardiovascular ProblemsHormone and Metabolic Research, 2011
- Determination and pharmacokinetics of periplocin in rat plasma by LC‐MSBiomedical Chromatography, 2010
- Gene expression profiling of the proliferative effect of periplocin on mouse cardiac microvascular endothelial cellsChinese Journal of Integrative Medicine, 2010
- Periplocin Inhibits Growth of Lung Cancer in vitro and in vivo by Blocking AKT/ERK Signaling PathwaysCellular Physiology and Biochemistry, 2010